Scholarlink

Objective <p>To assess the prevalence and persistence of self-reported depression and its associated factors in patients with systemic lupus erythematosus (SLE), using a patient-reported outcome measure in a large, multicentre, prospective cohort.</p> Methods <p>We conducted a longitudinal analysis of patients enrolled in the RELESSER-PROS registry who responded to item 7 (“I was depressed”) of the Lupus Impact Tracker questionnaire (LITQ7) over five annual visits. Self-reported depression was defined as any response other than “none of the time.” Covariates assessed at each visit included: age, disease duration, SELENA-SLEDAI (S-SLEDAI), glucocorticoid (GC) use, SLICC/ACR Damage Index (SDI), fibromyalgia, Charlson index, BMI, smoking status, menopause, sedentary lifestyle, marital and employment status. Generalized estimating equation (GEE) models were used to examine longitudinal associations.</p> Results <p>Of 1463 patients (mean age 55 years; 90% female), 89.9% reported depressive symptoms at least once; 26.5% reported feeling depressed “most of the time” at all five visits. Patients with self-reported depression in LIT accumulated significantly more damage over time (<i>p</i> = 0.009). In multivariable analysis, fibromyalgia (OR 2.90; 95% CI: 1.58–5.33) and GC use (OR 1.85; 95% CI: 1.17–2.93) were independently associated with self-reported depression.</p> Conclusions <p>Self-reported depression is highly prevalent and often persistent among patients with SLE. Its association with potentially modifiable factors such as GC use and fibromyalgia highlights the value of integrating patient-reported outcomes such as LIT into longitudinal care, potentially contributing to improve emotional well-being.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Self-reported depression on the Lupus Impact Tracker questionnaire (LIT) is associated with glucocorticoid use and fibromyalgia in systemic lupus erythematosus, according to RELESSER-PROS registry data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月24日

查看全文
  • Inigo Rua-Figueroa,
  • Julia Martínez-Barrio,
  • Zulema Plaza,
  • Norman Jiménez,
  • Maria Galindo-Izquierdo,
  • Esther Uriarte,
  • Antonio Fernandez-Nebro,
  • Jaime Calvo Alen,
  • José Rosas,
  • Javier Narváez,
  • Elena Aurrecoechea,
  • Mercedes Freire,
  • Eva Tomero,
  • Clara Sanguesa,
  • Carlota Iniguez,
  • Ana Perez,
  • Sandra Garrote,
  • Nuria Lozano-Rivas,
  • Oihane Ibarguengoitia,
  • Eva Salgado,
  • Celia Erausquin,
  • Tarek Carlos Salman Monte,
  • Raúl Menor,
  • Irene Altabás-González,
  • Jorge Fragio Gil ,
  • Joan M. Nolla,
  • Jose M. Pego-Reigosa

摘要

Objective

To assess the prevalence and persistence of self-reported depression and its associated factors in patients with systemic lupus erythematosus (SLE), using a patient-reported outcome measure in a large, multicentre, prospective cohort.

Methods

We conducted a longitudinal analysis of patients enrolled in the RELESSER-PROS registry who responded to item 7 (“I was depressed”) of the Lupus Impact Tracker questionnaire (LITQ7) over five annual visits. Self-reported depression was defined as any response other than “none of the time.” Covariates assessed at each visit included: age, disease duration, SELENA-SLEDAI (S-SLEDAI), glucocorticoid (GC) use, SLICC/ACR Damage Index (SDI), fibromyalgia, Charlson index, BMI, smoking status, menopause, sedentary lifestyle, marital and employment status. Generalized estimating equation (GEE) models were used to examine longitudinal associations.

Results

Of 1463 patients (mean age 55 years; 90% female), 89.9% reported depressive symptoms at least once; 26.5% reported feeling depressed “most of the time” at all five visits. Patients with self-reported depression in LIT accumulated significantly more damage over time (p = 0.009). In multivariable analysis, fibromyalgia (OR 2.90; 95% CI: 1.58–5.33) and GC use (OR 1.85; 95% CI: 1.17–2.93) were independently associated with self-reported depression.

Conclusions

Self-reported depression is highly prevalent and often persistent among patients with SLE. Its association with potentially modifiable factors such as GC use and fibromyalgia highlights the value of integrating patient-reported outcomes such as LIT into longitudinal care, potentially contributing to improve emotional well-being.